DPD3 Stock Overview
A urologic oncology company, focuses on the research, development, and commercialization of medical devices in the bio-chemistry industry. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Imagin Medical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.13 |
| 52 Week Low | CA$0.0005 |
| Beta | 1.15 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -98.81% |
| 33 Year Change | -99.85% |
| 5 Year Change | -99.95% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| DPD3 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | 0.2% |
| 1Y | -98.8% | -6.8% | 8.5% |
Return vs Industry: DPD3 underperformed the German Medical Equipment industry which returned -10.8% over the past year.
Return vs Market: DPD3 underperformed the German Market which returned 2% over the past year.
Price Volatility
| DPD3 volatility | |
|---|---|
| DPD3 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: DPD3's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine DPD3's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | n/a | Jim Hutchens | imaginmedical.com |
Imagin Medical Inc., a urologic oncology company, focuses on the research, development, and commercialization of medical devices in the bio-chemistry industry. It offers the i/Blue Imaging System, which detects bladder cancer with advanced proprietary optics and light sensors; and enCage Coil, a disposable and focal therapy precision ablation device for use in the treatment of prostate cancer. The company is also developing technologies to visualize and treat urologic cancers through minimally invasive surgery, including bladder and prostate cancer.
Imagin Medical Inc. Fundamentals Summary
| DPD3 fundamental statistics | |
|---|---|
| Market cap | €110.31k |
| Earnings (TTM) | -€2.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs DPD3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DPD3 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$3.32m |
| Earnings | -CA$3.32m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -91.8% |
How did DPD3 perform over the long term?
See historical performance and comparison